9 completed, 4 terminated, 3 recruiting, 2 unknown. 8 Phase 2, 6 Not applicable, 5 Phase 1, 2 Phase 3.
Follow Neoplasms, Lung: new trials by email Literature Review of Neoplasms, Lung trials Research Report on Neoplasms, Lung
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) Risvutatug rezetecan, Ivonescimab - Neoplasms, Lung | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 184 | 2026-09-09 | 2026-09-23 |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] Risvutatug rezetecan (Ris-Rez), Topotecan - Neoplasms, Lung | Phase 3 | Recruiting | GlaxoSmithKline | 420 | 2025-08-11 | 2026-10-20 |
| Precision Lung Cancer Survivorship Care Intervention Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program, Enhanced Usual Care - Lung Cancer, Pulmonary Neoplasm | Not applicable | Recruiting | Jerod L Stapleton, PhD | 300 | 2024-08-16 | 2026-02-23 |
| Study of ESG401 in Adults With Solid Tumors ESG401 - Neoplasms, Breast, Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Shanghai Escugen Biotechnology Co., Ltd | 156 | 2021-09-14 | 2025-09-12 |
| Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare® Moovcare® use - Lung Cancer, Neoplasms, Lung | Not applicable | Completed | UNC Lineberger Comprehensive Cancer Center | 41 | 2021-09-01 | 2023-10-10 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
| NEUWAVE Flexible Probe Study #2 Microwave ablation - Cancer of the Lung, Lung Cancer | Not applicable | Withdrawn | Ethicon, Inc. | 2020-07-31 | 2020-06-02 | |
| NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung Microwave Ablation - Cancer of Lung, Cancer of the Lung | Not applicable | Terminated | Ethicon, Inc. | 10 | 2018-06-29 | 2020-12-21 |
| Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer Lung Cancer, Lung Neoplasms | Completed | Mayo Clinic | 64 | 2016-12-01 | 2021-07-21 | |
| MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s) Microwave ablation - Lung Neoplasms, Cancer of Lung | Not applicable | Terminated | Mayo Clinic | 9 | 2016-06-08 | 2023-10-04 |
| Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma DNA Extraction - Carcinoma, Squamous Cell, Carcinoma, Squamous | Terminated | Mayo Clinic | 22 | 2015-04-08 | 2025-10-14 | |
| A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System Lung Cancer, Lung Neoplasms | Completed | Mayo Clinic | 23 | 2014-08-01 | 2018-03-21 | |
| The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine cancer stem cell vaccine - Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 40 | 2014-03-01 | 2019-09-12 |
| Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells cancer stem cell vaccine - Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 40 | 2014-03-01 | 2015-06-03 |
| A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Erlotinib, Docetaxel, Cisplatin - Neoplasms, Lung, Carcinoma, Non-Small Cell Lung | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2010-06-01 | 2010-05-27 |
| A Phase I Study of iPS Cell Generation From Patients With COPD Skin Biopsy - Thoracic Diseases, Respiratory Tract Diseases | Not applicable | Completed | Mayo Clinic | 31 | 2009-09-01 | 2022-09-28 |
| Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia propofol, remifentanil, sevoflurane - Lung Cancer, Neoplasms, Lung | Unknown | Asan Medical Center | 400 | 2007-10-01 | 2009-07-09 | |
| Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy talabostat, pemetrexed - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 3 | Terminated | Point Therapeutics | 400 | 2006-02-01 | 2007-06-08 |
| Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) - Pulmonary Diseases, Neoplasms, Lung | Phase 2 | Completed | Sanofi | 98 | 2006-01-01 | 2012-12-10 |
| A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. Gemcitabine, Carboplatin, LY900003 - Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms | Phase 2 | Completed | Eli Lilly and Company | 2002-06-01 | 2006-07-19 |
Lung Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (10) · Carcinoma, Squamous Cell (4) · Adenocarcinoma (3) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Small Cell (1) · Disease (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Ovarian Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1)
Neoplasms by Site (20) · Respiratory Tract Neoplasms (20) · Thoracic Neoplasms (20) · Lung Diseases (19) · Respiratory Tract Diseases (19) · Neoplasms (18) · Bronchial Neoplasms (11) · Carcinoma, Bronchogenic (11) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Neoplasms, Squamous Cell (4) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Colonic Diseases (2)
Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · ISIS 3521 (1) · JDQ443 (1) · Pemetrexed (1) · Propofol (1) · Remifentanil (1) · Sevoflurane (1) · Topotecan (1) · aflibercept (1) · talabostat (1) · tislelizumab (1)
Mayo Clinic (5) · Ethicon, Inc. (2) · Fuda Cancer Hospital, Guangzhou (2) · GlaxoSmithKline (2) · Asan Medical Center (1) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · Jerod L Stapleton, PhD (1) · Novartis Pharmaceuticals (1) · Point Therapeutics (1) · Sanofi (1) · Shanghai Escugen Biotechnology Co., Ltd (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (15) · China (5) · Canada (3) · France (3) · Japan (3) · South Korea (3) · Australia (2) · Germany (2) · Italy (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Denmark (1)
Dennis Wigle, MD, PhD (2) · Aaron Mansfield, MD (1) · Bradley Pua, MD (1) · Dennis A Wigle, MD, PhD (1) · Fei Ma (1) · Gita Mody, MD, MPH (1) · In Cheol Choi, MD, PhD (1) · Jae Kim, MD (1) · Jamie L Studts, PhD (1) · Janani Reisenauer, MD (1) · Jerod L Stapleton, PhD (1) · Liang-An Chen, M.D., Ph.D. (1) · Michael Pritchett, MD (1) · Shanda Blackmon, MD, MPH (1)
PMID 22473314, PMID 20593550, PMID 36399068, PMID 39216478, PMID 40359710, PMID 40850860
2025 (1), R01CA254734 (1)